Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/18074
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGleeson, M-
dc.contributor.authorCounsell, Nicholas-
dc.contributor.authorCunningham, D-
dc.contributor.authorChadwick, N-
dc.contributor.authorLawrie, A-
dc.contributor.authorHawkes, Eliza A-
dc.contributor.authorMcMillan, A-
dc.contributor.authorArdeshna, K M-
dc.contributor.authorJack, A-
dc.contributor.authorSmith, P-
dc.contributor.authorMouncey, P-
dc.contributor.authorPocock, C-
dc.contributor.authorRadford, J A-
dc.contributor.authorDavies, J-
dc.contributor.authorTurner, D-
dc.contributor.authorKruger, A-
dc.contributor.authorJohnson, P-
dc.contributor.authorGambell, J-
dc.contributor.authorLinch, D-
dc.date.accessioned2018-07-10T06:36:54Z-
dc.date.available2018-07-10T06:36:54Z-
dc.date.issued2017-10-01-
dc.identifier.citationAnnals of Oncology: Official Journal of the European Society for Medical Oncology 2017; 28(10): 2511-2516en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/18074-
dc.description.abstractCentral nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is associated with a dismal prognosis. Here, we report an analysis of CNS relapse for patients treated within the UK NCRI phase III R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) 14 versus 21 randomised trial. The R-CHOP 14 versus 21 trial compared R-CHOP administered two- versus three weekly in previously untreated patients aged ≥18 years with bulky stage I-IV DLBCL (n = 1080). Details of CNS prophylaxis were retrospectively collected from participating sites. The incidence and risk factors for CNS relapse including application of the CNS-IPI were evaluated. 177/984 patients (18.0%) received prophylaxis (intrathecal (IT) methotrexate (MTX) n = 163, intravenous (IV) MTX n = 2, prophylaxis type unknown n = 11 and IT MTX and cytarabine n = 1). At a median follow-up of 6.5 years, 21 cases of CNS relapse (isolated n = 11, with systemic relapse n = 10) were observed, with a cumulative incidence of 1.9%. For patients selected to receive prophylaxis, the incidence was 2.8%. Relapses predominantly involved the brain parenchyma (81.0%) and isolated leptomeningeal involvement was rare (14.3%). Univariable analysis demonstrated the following risk factors for CNS relapse: performance status 2, elevated lactate dehydrogenase, IPI, >1 extranodal site of disease and presence of a 'high-risk' extranodal site. Due to the low number of events no factor remained significant in multivariate analysis. Application of the CNS-IPI revealed a high-risk group (4-6 risk factors) with a 2- and 5-year incidence of CNS relapse of 5.2% and 6.8%, respectively. Despite very limited use of IV MTX as prophylaxis, the incidence of CNS relapse following R-CHOP was very low (1.9%) confirming the reduced incidence in the rituximab era. The CNS-IPI identified patients at highest risk for CNS recurrence. ISCRTN number 16017947 (R-CHOP14v21); EudraCT number 2004-002197-34.en_US
dc.language.isoeng-
dc.subjectcentral nervous systemen_US
dc.subjectdiffuse large B-cell lymphomaen_US
dc.subjectrelapseen_US
dc.subjectrituximaben_US
dc.titleCentral nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleAnnals of Oncology: Official Journal of the European Society for Medical Oncologyen_US
dc.identifier.affiliationDepartment of Medicine, The Royal Marsden Hospital, London and Surrey, UKen_US
dc.identifier.affiliationCancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UKen_US
dc.identifier.affiliationMedical Oncologyen_US
dc.identifier.affiliationDepartment of Medical Oncology, Eastern Health, Melbourne, Australiaen_US
dc.identifier.affiliationDepartment of Haematology, Nottingham City Hospital, Nottingham, UKen_US
dc.identifier.affiliationDepartment of Haematology, University College London, London, UKen_US
dc.identifier.affiliationDepartment of Haematology, Mount Vernon Cancer Centre, Northwood, UKen_US
dc.identifier.affiliationHMDS, Leeds Teaching Hospitals NHS Trust, Leeds, UKen_US
dc.identifier.affiliationDepartment of Haematology, East Kent Hospitals, Canterbury, UKen_US
dc.identifier.affiliationThe University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UKen_US
dc.identifier.affiliationDepartment of Haematology, Western General Hospital, Edinburgh, UKen_US
dc.identifier.affiliationDepartment of Haematology, Torbay Hospital, Torquay, UKen_US
dc.identifier.affiliationDepartment of Haematology, Royal Cornwall Hospital, Truro, UKen_US
dc.identifier.affiliationCancer Research UK Centre, Southampton, UKen_US
dc.identifier.affiliationClinical Haematologyen_US
dc.identifier.doi10.1093/annonc/mdx353en_US
dc.type.contentTexten_US
dc.identifier.pubmedid28961838-
dc.type.austinClinical Trial, Phase III-
dc.type.austinJournal Article-
dc.type.austinRandomized Controlled Trial-
local.name.researcherHawkes, Eliza A
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.languageiso639-1en-
crisitem.author.deptClinical Haematology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptInfectious Diseases-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

28
checked on Mar 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.